14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 3.134 1 day ( 0 % )
Last Price JP¥64.00 4.92 %
High/ Low JP¥60.00 - JP¥65.00 6.67%
Chg 7 Days 1.59 % $63.00 JP¥64.00
Chg 30 Days 8.47 % $59.00 JP¥64.00
Chg 12 mos -53.28 % $137.00 JP¥64.00
Trend - 3 mos -7.69 % Width: 21.29 %
Trend - 12 mos -56.27 % Width: 75.06 %
Pred. range - 3 mos JP¥48.71 - JP¥59.08 -23.90 % - -7.69 %
Pred. range - 12 mos JP¥18.27 - JP¥31.98 -71.45 % - -50.02 %
Short MA avg 3 mos Sell Jun 10, 2024 - 5 days
Long MA avg 3 mos Buy May 31, 2024 - 11 days
Short/Long MA avg 3 mos Buy Jun 04, 2024 - 9 days
Short MA avg 12 mos Buy May 31, 2024 - 11 days
Long MA avg 12 mos Sell Sep 29, 2023 - 173 days
Short/Long MA avg 12 mos Sell Nov 30, -1 - N/A days
Pivot Short Buy Feb 27, 2024 - 75 days
Bollinger Buy Jun 14, 2024 - 1 day
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About BrightPath Biotherapeutics Co.,Ltd.

BrightPath Biotherapeutics Co.Ltd. BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pl... 4594.T Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT